DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gj9kl7/therapy_class) has announced the addition of the "Therapy Class Overview : Hepatitis C Virus Infection" report to their offering.
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead's Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gilead's Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enanta's (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!
Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria.
A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gilead’s Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!
Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries.
In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
What one would get if buy this report?
- Noteworthy progress in the Oral IFN –Free combinations for Treatment of HCV and ROW opportunity
- Competitive Landscape - IFN-Free drugs
- HCV Vaccines and their progress
- Difficult to treat and drugs for HCV-HIV co infection
- Market size opportunity to 2020
Key Topics Covered:
Executive Summary
Progress in the Clinical Development of HCV drugs
Competitive Landscape - IFN-Free drugs
Market Dynamics- Present and Future
HCV Vaccines
HCV-HIV Co infection
Annexure
Products Mentioned
- ABT-450
- ABT-47
- Abbott
- BMY
- GILD
- GS-5885
- HCV
- HIV-HCV Co-infection
- IFN-Free
- Idenix
- Liver cirrhosis
- NS5A inhibitor
- Non-responders
- Oral
- Polymerase inhibitor
- Protease inhibitor
- SVR
- Sofosbuvir
- Sustained virologic response
- VRTX
- VX-135
- Vaccine
For more information visit http://www.researchandmarkets.com/research/gj9kl7/therapy_class
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
